Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk
Pressmeddelanden • Sep 14, 2017 18:27 CEST
Largest and most inclusive patient population of any GLP-1 CV outcomes trial with 14,500 patients at 687 trial sites across 35 countries Full trial results presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in the New England Journal of Medicine
Pressmeddelanden • Sep 14, 2017 08:03 CEST
Agreement builds on 2016 collaboration on commercialisation rights to anaesthetic medicines in markets outside the US
AstraZeneca presents new results identifying severe asthma patients who would benefit most from Benralizumab
Pressmeddelanden • Sep 11, 2017 10:11 CEST
Further analysis of the Phase III trials, SIROCCO and CALIMA, reinforces benralizumab’s efficacy and identifies more frequent prior exacerbations and/or greater baseline blood eosinophil count as key predictors of an enhanced treatment effect. Findings pave the way for a personalised treatment approach to guide more precise selection of the benralizumab-responsive patient.
AstraZeneca's Tagrisso shows potential as a new standard of care in 1st-line EGFR-mutated lung cancer at ESMO 2017 Congress
Pressmeddelanden • Sep 09, 2017 00:22 CEST
Pressmeddelanden • Sep 07, 2017 16:52 CEST
Vi vill uppmärksamma patienter som hämtat ut en förpackning med SelokenZOC 100 mg i burk med 100 tabletter, efter april i år, att kontrollera att den burk som ligger i förpackningen verkligen är märkt SelokenZOC 100 mg. Aktuellt varunummer är Vnr 543587, batchnummer VBBN.
Pressmeddelanden • Sep 07, 2017 14:02 CEST
AstraZeneca and MedImmune, its global biologics research and development arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme.
Pressmeddelanden • Sep 07, 2017 08:09 CEST
Phase III AMPLIFY trial demonstrateda statistically significant improvement in lung function in patients with COPD Study achieved the primary endpoints to support a New Drug Application (NDA) submission
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
Pressmeddelanden • Sep 06, 2017 23:05 CEST
AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma
AstraZeneca to present data on next generation of biologics at European Respiratory Society International Congress 2017
Pressmeddelanden • Sep 04, 2017 08:03 CEST
AstraZeneca and its global biologics research and development arm, MedImmune, will present new data on its respiratory portfolio and pipeline at the European Respiratory Society (ERS) International Congress, 9-13 September 2017 in Milan, Italy. The breadth and depth of science are reflected in the 48 accepted abstracts.....
Pressmeddelanden • Aug 31, 2017 08:11 CEST
More than 40 presentations, including data from two pivotal trials selected as late-breaking abstracts for oral presentation in the ESMO Presidential Symposia Phase III PACIFIC data reinforce potential of Imfinzi following US FDA breakthrough therapy designation in locally-advanced (Stage III) unresectable NSCLC
AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson’s disease
Pressmeddelanden • Aug 29, 2017 08:33 CEST
Pressmeddelanden • Aug 28, 2017 08:03 CEST
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy.
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
Pressmeddelanden • Aug 24, 2017 08:03 CEST
AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking low-dose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.
Pressmeddelanden • Aug 17, 2017 21:27 CEST
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib).
Nordiska registerdata visar att SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för prematur hjärt-kärlsjukdom och död
Pressmeddelanden • Aug 16, 2017 09:00 CEST
Resultat publicerade i The Lancet Diabetes & Endocrinology från observationsstudien CVD-REAL Nordic, baserad på svenska registerdata, indikerar att behandling av typ 2-diabetes med SGLT-2-hämmare i klinisk praxis är associerad med minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.
Pressmeddelanden • Aug 02, 2017 08:04 CEST
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.
Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma
Pressmeddelanden • Aug 01, 2017 08:07 CEST
AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib .
Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer
Pressmeddelanden • Jul 31, 2017 08:04 CEST
Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.
Tagrisso significantly improves progression-free survival in the phase III FLAURA trial for lung cancer
Pressmeddelanden • Jul 27, 2017 09:19 CEST
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment......